By Connor Hart
Shares of iSpecimen gained after securing suppliers for the flu-like human metapneumovirus, a virus which causes upper respiratory infections.
The stock rose 22%, to $3.50, in after-hours trading Thursday. Shares ended the regular session 8% higher, at $2.85, putting them down 71% over the last year.
The online marketplace for human biospecimens said the virus has been causing hospitals in China to become overrun, and that it has raised concerns of another public-health pandemic.
"There is currently no vaccine for HMPV, hence the potential need for samples if a company were looking to make this type of breakthrough drug or study the virus," iSpecimen said in a Securities and Exchange Commission filing.
It added the potential demand for a vaccine for the virus highlights the need for reliable access to high-quality specimens.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 16, 2025 18:19 ET (23:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。